CSTL icon

Castle Biosciences
CSTL

39.27 USD
-0.13
0.33%
At close Updated Dec 29, 4:00 PM EST
Pre-market
After hours
39.27
0.00
0%
1 day
-0.33%
5 days
-1.82%
1 month
0.38%
3 months
75.63%
6 months
92.31%
Year to date
40.05%
1 year
47.3%
5 years
-41.24%
10 years
83.5%
 

About: Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Employees: 823

Healthcare Diagnostics & Research
0
Funds holding %
of 7,528 funds
Explore Fund Trends
0
Analysts bullish %
of 3 analysts
See Analyst Outlook
0
Positive news %
of 8 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™